Cequent Pharma raises $9 million for RNAi
Cequent Pharmaceuticals, a Cambridge, Mass., developer of drugs based on a new gene-silencing technology, raised $9 million in a first-round funding. The round was led by the Novartis Option Fund, joined by Ampersand Ventures, Nexus Medical Partners, and Pappas Ventures.
Cequent is developing new treatments based… Continue Reading